Grifols (GRFS) Receivables (2009 - 2025)
Grifols' (GRFS) quarterly Receivables came in at $916.1 million in Q4 2025, up 9.49% YoY from $836.7 million in Q4 2024, and up 9.49% on a QoQ basis from $836.7 million in Q4 2024.
Grifols (GRFS) Receivables (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Receivables data on file, last reported at $916.1 million in Q4 2025.
- Quarterly Receivables rose 9.49% year-over-year to $916.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $916.1 million (up 9.49% YoY) and the FY2025 annual result came in at $916.1 million, up 4.61% from the prior year.
- Receivables advanced to $916.1 million in Q4 2025, from $836.7 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $916.1 million in Q4 2025 to a low of $571.7 million in Q4 2021.
- A 5-year average of $785.6 million and a median of $828.7 million in 2022 frame the typical range for Receivables.
- Annual changes were most pronounced in 2021 — Receivables decreased 7.82% — and 2022, when it soared 44.96%.
- Tracing GRFS's Receivables over 5 years: stood at $571.7 million in 2021, then soared by 44.96% to $828.7 million in 2022, then retreated by 6.51% to $774.7 million in 2023, then gained by 8.0% to $836.7 million in 2024, then rose by 9.49% to $916.1 million in 2025.
- The last three Receivables figures came in at $916.1 million (Q4 2025), $836.7 million (Q4 2024), and $774.7 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 470.28 Bn | 463.71 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 378.50 Bn | 371.36 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 302.91 Bn | 295.22 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 259.04 Bn | 254.14 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 237.16 Bn | 223.17 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 183.02 Bn | 179.84 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 160.85 Bn | 149.16 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 105.85 Bn | 101.69 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Grifols | 5.47 Bn | 4.47 Bn | - | 757.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 916.10 Mn |
| Dec 31, 2024 | 836.71 Mn |
| Dec 31, 2023 | 774.73 Mn |
| Dec 31, 2022 | 828.67 Mn |
| Dec 31, 2021 | 571.65 Mn |
| Dec 31, 2020 | 620.18 Mn |
| Sep 30, 2020 | 663.81 Mn |
| Mar 31, 2020 | 560.38 Mn |
| Dec 31, 2019 | 543.01 Mn |
| Sep 30, 2019 | 516.62 Mn |
| Mar 31, 2019 | 678.24 Mn |
| Dec 31, 2018 | 460.88 Mn |
| Sep 30, 2018 | 538.34 Mn |
| Jun 30, 2018 | 496.17 Mn |
| Mar 31, 2018 | 496.64 Mn |
| Dec 31, 2017 | 454.97 Mn |
| Jun 30, 2017 | 512.98 Mn |
| Dec 31, 2016 | 576.21 Mn |
| Sep 30, 2016 | 530.43 Mn |
| Jun 30, 2016 | 626.95 Mn |